Emicizumab (Hemlibra®, Roche Pharma AG) is a humanised,
modified, monoclonal immunoglobulin G4 (IgG4) antibody with
a bispecific antibody structure. Emicizumab substitutes part of
the cofactor function of activated factor VIII (FVIIIa) by bridging
activated factor IX (FIXa) and factor X (FX) to restore effective
haemostasis in HA individuals.
File type:
pdf
File size:
549 KB
Release:
29-10-21
